logo
  

DTE Energy Q1 Profit Tops View, Backs Full Year Outlook - Quick Facts

DTE Energy (DTE) Friday said its first-quarter earnings fell to $273 million or $1.53 per share from $326 million or $1.84 per share in 2014.

Excluding items, operating earnings were $1.65 per share, while it totaled $1.69 per share last year. On average, 9 analysts polled by Thomson Reuters expected earnings of $1.53 per share for the quarter. Analysts' estimates typically exclude special items.

Operating revenues dropped to $2.984 billion from $3.930 billion. Analysts expected revenues of $3.53 billion.

Gerard Anderson, DTE Energy chairman and CEO, said, "DTE Energy's solid first quarter performance sets us squarely on the path to achieve our financial and operational goals for 2015."

Further, DTE Energy reiterated its 2015 operating earnings per share guidance of $4.48 to $4.72. Analysts look for earnings of $4.62 per share.

For comments and feedback contact: editorial@rttnews.com

Business News

Editors Pick
While reporting financial results for the first quarter on Wednesday, medical devices company Boston Scientific Corp. (BSX) raised its adjusted earnings and net sales growth guidance for the full-year 2024. For fiscal 2024, the company now projects earnings in a range of $1.43 to $1.48 per share and... Shares of Roche Holding AG were losing around 3 percent in Switzerland after the drug major reported weak sales in its first quarter and confirmed fiscal 2024 outlook. Excluding COVID-19-related products, quarterly sales increasedy 7 percent. For fiscal 2024, Roche continues to expect an increase in group sales in the mid single digit range at constant exchange rates. Dr. Reddy's Laboratories Ltd. is recalling six lots of Sapropterin Dihydrochloride Powder for Oral Solution 100 mg to the consumer level. According to the U.S. Food and Drug Administration, the recall was due to powder discoloration in some packets leading to decreased potency.

This week, we feature Nigeria’s combat with meningitis, Hostile takeover bid for Vanda Pharma, US opioid crisis, Sammy’s Milk’s safety concerns, and X4’s Mavorixafor’s fast-track status.

View More Videos
RELATED NEWS
Follow RTT